Last reviewed · How we verify

NCT03999359

A Self-Help Metacognitive Therapy for Cardiac Rehabilitation Patients (PATHWAY WS3)

Terminated NA Last updated 22 March 2023
What this trial tests

NA trial testing Home-based Metacognitive Therapy in Depression in 242 participants. Terminated before completion.

Timeline
14 May 2019
Primary endpoint
7 August 2020
7 August 2020

Quick facts

Lead sponsorUniversity of Manchester
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment242
Start date14 May 2019
Primary completion7 August 2020
Estimated completion7 August 2020
Sites5 locations across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Manchester

Who can join

18 and older, any sex, with Depression or Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Depression and anxiety are highly prevalent in people with heart disease, causing immense human and economic burden. Available pharmacological and psychological interventions have limited efficacy and the needs of these patients are not being met in cardiac rehabilitation services despite emphasis in key NHS policy. Extensive evidence shows that a particular style of thinking dominated by rumination (dwelling on the past) and worry maintains emotional distress. A psychological intervention called metacognitive therapy (MCT) that reduces this style of thinking alleviates depression and anxiety in mental health settings. This is a single-blind feasibility randomised controlled trial of metacognitive therapy delivered in a self-help format (Home-MCT). The aim of the study is to evaluate the acceptability and feasibility of integrating Home-MCT into cardiac rehabilitation services and to evaluate the effectiveness and cost-effectiveness of Home-MCT.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Metacognitive therapy home-based self-help for anxiety and depression in cardiovascular disease patients in the UK: A single-blind randomised controlled trial.
    Wells A, Reeves D, Heal C, Fisher P, et al · · 2023 · cited 12× · PMID 36719886 · DOI 10.1371/journal.pmed.1004161
  2. Evaluating Metacognitive Therapy to Improve Treatment of Anxiety and Depression in Cardiovascular Disease: The NIHR Funded PATHWAY Research Programme.
    Wells A, Reeves D, Heal C, Davies LM, et al · · 2022 · cited 12× · PMID 35722590 · DOI 10.3389/fpsyt.2022.886407
  3. Metacognitive therapy self-help for anxiety-depression: Single-blind randomized feasibility trial in cardiovascular disease.
    Wells A, Reeves D, Heal C, Fisher P, et al · · 2022 · cited 7× · PMID 35467904 · DOI 10.1037/hea0001168
  4. Improving the Effectiveness of Psychological Interventions for Depression and Anxiety in Cardiac Rehabilitation: The PATHWAY Research Programme Including 4 RCTs
    Wells A, Reeves D, Fisher P, Davies L, et al · · 2024 · PMID 39353053

Verify or expand the search:

Other recruiting trials for Depression

Currently open trials in the same condition.

Other University of Manchester trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03999359.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing